Exosome Therapy

Exosomes are nanoscale extracellular vesicles — membrane packets that cells shed, carrying proteins, lipids and RNA between cells — and they are genuinely one of biology's hot fields: intercellular communication, candidate drug-delivery vehicles, liquid-biopsy diagnostics, and the proposed mediators of whatever benefits mesenchymal stem cells produce (the “cells work through their secretions” hypothesis that made exosomes the stem-cell industry's natural sequel). The single fact that frames this entire hub: no exosome product is approved as a therapy by any major regulator anywhere — not the FDA, not the EMA — for any condition; every exosome injection, infusion or inhalation sold today is an unapproved biological drug by the regulators' own explicit statements. That is not a technicality about paperwork: it means no product on this market has demonstrated identity, purity, potency or clinical benefit to any independent standard — the manufacturing question (what is actually in the vial?) being, as the harm record shows, the operative one.

The exosome industry earned its regulatory debut the hard way: in 2019, patients in Nebraska were hospitalised with serious bacterial infections — sepsis among them — after receiving unapproved “exosome” products marketed through clinics, prompting the FDA's first public safety notification on exosomes: stating plainly that no approved exosome products exist, that clinics were deceiving patients with unsubstantiated claims, and that the agency had received multiple adverse-event reports. The episode is this hub's anchor because it demonstrated the failure chain in one incident: an unregulated manufacturer, an unvalidated product (contaminated, whatever its vesicle content), a clinic network retailing it on regenerative-medicine language, and patients paying thousands for hospitalisation. Warning letters to exosome manufacturers and clinics have continued since — COVID-era cure claims included, on schedule — while the market adapted the way this collection's marketplace files predict: rebranding, jurisdiction-hopping, and migration toward the cosmetic tier where the next message finds it.

Today's exosome economy runs on two tiers. The clinical tier: injections and IV infusions sold for joints and orthopaedics (the PRP/stem-cell menu's new line), hair restoration, anti-ageing and longevity, autism (the saddest recurring entry in this collection's marketplace files), long COVID, neurodegenerative disease and “immune optimisation” — at $3,000-10,000+ per course, on evidence consisting of preclinical studies, small uncontrolled series and borrowed stem-cell citations; no adequate randomised trial supports any of it, and the products' actual contents (vesicle counts, source cells, contaminants) are whatever the unregulated manufacturer says. The cosmetic flank: “exosome” serums and post-microneedling ampoules — often plant-derived or cell-culture-media products of debatable vesicle content — occupying the topical-cosmetic regulatory gap where claims stay vague enough to avoid drug status; lower stakes than the needles, same borrowed-science branding. The through-line is the stem-cell-clinic playbook, updated: harder-to-characterise product, fresher vocabulary, identical economics — and the same tell, that the menu of treatable conditions is the seller's ambition rather than any trial's finding.

The honest counterweight: exosome research deserves its excitement. Drug delivery — engineering vesicles to carry therapeutics across biological barriers (the blood-brain barrier included) — is a serious pharmaceutical programme; diagnostics — reading tumour-derived exosomes in blood — is advancing within the liquid-biopsy field; and therapeutic candidates (MSC-derived exosome preparations for inflammatory and degenerative conditions) are in early-phase registered trials with actual characterisation standards, the legitimate pathway the clinic market impersonates. The field's own scientists are this hub's best witnesses: the International Society for Extracellular Vesicles has repeatedly warned against unproven exosome therapies, publishing position papers distinguishing the research (rigorous, early, standardisation-obsessed — because defining what counts as an exosome dose is itself unsolved) from the clinics (selling that unsolved product today). The gap between a field working on identity-and-potency standards and a market retailing vials without them is the entire distance between medicine and this menu — and it will close through trials and approvals, visibly, if and when it closes.

Exosomes complete a recognisable succession — PRP, stem cells, exosomes — each inheriting the last's clinics, claims and customers, and the pattern-recognition toolkit transfers. The tells: “more powerful than stem cells” (comparative claims between two unproven products), the universal menu (joints to autism to ageing — one vial, all diseases), autologous-adjacent reassurance (“natural cell messengers” doing the “your own blood” job), borrowed-literature citation (preclinical vesicle papers footnoting clinical price lists), regulatory doublespeak (“FDA-registered lab” — registration is an address on file, not approval), and the trial-avoidance economics: a genuine therapeutic this promising would be worth billions through approval — selling it per-vial in strip-mall clinics is what you do with product that cannot survive characterisation. The counter-questions, as ever, cost nothing: which approved product (none exist — the answer is the test), which randomised trial for my condition, what exactly is in the vial and who verified it, and why is this available here before it is available as medicine anywhere.

Decline all injectable and IV exosome offers — joints, hair, ageing, autism, long COVID, everything: no approved exosome therapy exists anywhere, no adequate trial supports any clinic indication, the products are uncharacterised unapproved biologics, and the market's founding incident was a sepsis cluster; the $5,000 is not buying early access to the future — the actual future is running registered trials you can join for free. For the cosmetic serums: discretionary money on marketing-tier science — likely harmless topically, unverifiable contents, and the “exosome” on the label is doing brand work; buy skincare on its own evidence (retinoids, sunscreen — the boring proven list). If a condition on the exosome menu is yours — arthritis, hair loss, a child's autism, long COVID: each has an honest hub in this collection with its real options and its real frontiers; the menu's targeting of exactly those conditions is its business model, not its evidence. And keep the succession pattern on file: when the next vesicle, peptide or particle inherits these clinics — the vocabulary will be new and the four counter-questions will still work.